2026/08/30
Shanghai, August 30, 2026 – WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim dividend of RMB 1.03 billion in 2025, the Company has further increased its 2026 interim dividend payout to RMB 1.51 billion. While accelerating the expansion of global capacity and capabilities, the Company remains committed to returning value to shareholders.
Read more2026/08/03
WuXi AppTec, a leading global pharmaceutical CRDMO, today announced financial results for the first half ending June 30, 2026. The Company raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers' products and its unique integrated CRDMO platform.
Read more2026/07/21
SHANGHAI, July 21, 2026 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announced it has been named in the FTSE4Good Index Series for the fourth consecutive year, reflecting the Companys' sustained commitment to sustainability.
Read more2026/06/12
We are reaching out to make you aware of a decisive action we are taking to address the U.S. Department of Defense’s erroneous designation of our company, and to protect the interests of our customers, partners, employees and shareholders.
Read more2026/06/09
We want to be absolutely clear: WuXi AppTec is not a Chinese military company — not based on an objective review of the facts, and not under the statutory designation criteria for the Section 1260H list under U.S. law.
Read more